Lancet Rheumatology最新文献

筛选
英文 中文
Research in Brief
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-24 DOI: 10.1016/S2665-9913(25)00036-0
Jennifer Thorley
{"title":"Research in Brief","authors":"Jennifer Thorley","doi":"10.1016/S2665-9913(25)00036-0","DOIUrl":"10.1016/S2665-9913(25)00036-0","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Page e162"},"PeriodicalIF":15.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new era of non-opioid analgesics?
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-24 DOI: 10.1016/S2665-9913(25)00035-9
The Lancet Rheumatology
{"title":"A new era of non-opioid analgesics?","authors":"The Lancet Rheumatology","doi":"10.1016/S2665-9913(25)00035-9","DOIUrl":"10.1016/S2665-9913(25)00035-9","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Page e145"},"PeriodicalIF":15.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thank you to The Lancet Rheumatology's peer reviewers in 2024
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-24 DOI: 10.1016/S2665-9913(25)00038-4
The Lancet Rheumatology Editors
{"title":"Thank you to The Lancet Rheumatology's peer reviewers in 2024","authors":"The Lancet Rheumatology Editors","doi":"10.1016/S2665-9913(25)00038-4","DOIUrl":"10.1016/S2665-9913(25)00038-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Pages e155-e158"},"PeriodicalIF":15.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-18 DOI: 10.1016/S2665-9913(24)00312-6
Walter P Maksymowych, Robert G W Lambert, Rebecca J Bolce, Natalia Bello, Baojin Zhu, Jeffrey R Lisse, Mikkel Østergaard
{"title":"The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.","authors":"Walter P Maksymowych, Robert G W Lambert, Rebecca J Bolce, Natalia Bello, Baojin Zhu, Jeffrey R Lisse, Mikkel Østergaard","doi":"10.1016/S2665-9913(24)00312-6","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00312-6","url":null,"abstract":"<p><strong>Background: </strong>The effect of biological disease-modifying antirheumatic drugs (DMARDs) on sacroiliac joint lesions over 52 weeks in biological DMARD-naive patients with radiographic axial spondyloarthritis is unknown. This post-hoc analysis evaluated the effect of ixekizumab and adalimumab versus placebo on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axial spondyloarthritis from the COAST-V study.</p><p><strong>Methods: </strong>COAST-V was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial with an active reference arm done over 52 weeks at 84 sites in 12 countries. Eligible patients were adults (aged ≥18 years) naive to biological DMARDs with active radiographic axial spondyloarthritis, radiographic evidence of sacroiliitis, and an inadequate response or intolerance to non-steroidal anti-inflammatory drugs. Patients were randomly assigned (1:1:1:1) to 80 mg ixekizumab every 2 weeks (Q2W) or every 4 weeks (Q4W), 40 mg adalimumab Q2W, or placebo. At week 16, patients receiving placebo or adalimumab were randomly assigned (1:1) again to ixekizumab Q2W or ixekizumab Q4W. Post-hoc analyses of patients with MRI available at baseline, 16 weeks, and 52 weeks are reported. MRIs were scored using the Spondyloarthritis Research Consortium of Canada sacroiliac joint structural scores for erosion, backfill, fat lesions, and ankylosis. ANCOVA was used for treatment comparisons in observed cases adjusting for baseline values, bone marrow oedema, and stratification factors. Subgroup analyses by sex, HLA-B27, and baseline bone marrow oedema were done.</p><p><strong>Findings: </strong>Between June 20, 2016, and Aug 22, 2017, 341 patients were enrolled in the COAST-V study. MRI scans were available for 325 (95%) of 341 patients at baseline and week 16, and for 301 (88%) patients at week 52. 264 (81%) of 325 patients were male and 61 (19%) were female, and the mean age was 41·5 years (SD 11·6). At week 16, erosion significantly decreased versus placebo in the ixekizumab Q2W group (least squares mean -0·91 [SE 0·19] vs 0·10 [0·18]; p<0·0001) and the ixekizumab Q4W group (-0·57 [SE 0·19]; p=0·0086]); the effect of adalimumab was similar. Backfill significantly increased from baseline to week 16 in ixekizumab Q2W versus placebo (0·52 [0·12] vs 0·04 [0·12]; p=0·0042). At week 16, decreases in erosion differed significantly between the placebo group and ixekizumab Q2W or Q4W groups, and differences were seen by sex, HLA-B27 status, and baseline bone marrow oedema score. At week 52, at both ixekizumab doses, further changes were observed in erosion and backfill, which were greatest with continuous ixekizumab Q2W (mean erosion -1·50 [SD 2·70], mean backfill 0·76 [SD 2·09]). A decrease in erosion was also noted in patients switching from adalimumab to ixekizumab at week 16. COAST-V was registered with ClinicalTrials.gov (NCT02696785).</p><p><strong>Interpretation: ","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological disease-modification in axial spondyloarthritis: insights from MRI.
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-18 DOI: 10.1016/S2665-9913(24)00352-7
Torsten Diekhoff, Sevtap Tugce Ulas
{"title":"Biological disease-modification in axial spondyloarthritis: insights from MRI.","authors":"Torsten Diekhoff, Sevtap Tugce Ulas","doi":"10.1016/S2665-9913(24)00352-7","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00352-7","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colchicine and cardiovascular protection in gout: unresolved questions – Authors' reply
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-07 DOI: 10.1016/S2665-9913(25)00025-6
Edoardo Cipolletta , Laila J Tata , Abhishek Abhishek
{"title":"Colchicine and cardiovascular protection in gout: unresolved questions – Authors' reply","authors":"Edoardo Cipolletta , Laila J Tata , Abhishek Abhishek","doi":"10.1016/S2665-9913(25)00025-6","DOIUrl":"10.1016/S2665-9913(25)00025-6","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Page e161"},"PeriodicalIF":15.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colchicine and cardiovascular protection in gout: unresolved questions
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-07 DOI: 10.1016/S2665-9913(25)00024-4
Masanari Kuwabara , Naoyuki Ohtani , Ichiro Hisatome
{"title":"Colchicine and cardiovascular protection in gout: unresolved questions","authors":"Masanari Kuwabara , Naoyuki Ohtani , Ichiro Hisatome","doi":"10.1016/S2665-9913(25)00024-4","DOIUrl":"10.1016/S2665-9913(25)00024-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Pages e160-e161"},"PeriodicalIF":15.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-05 DOI: 10.1016/S2665-9913(25)00028-1
Sijia Liu , Jialao Ma
{"title":"Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis","authors":"Sijia Liu , Jialao Ma","doi":"10.1016/S2665-9913(25)00028-1","DOIUrl":"10.1016/S2665-9913(25)00028-1","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Page e159"},"PeriodicalIF":15.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial.
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-05 DOI: 10.1016/S2665-9913(24)00373-4
Michelle Hall, Kim Allison, Gabrielle Knox, Fiona McManus, Rana S Hinman, Kim L Bennell, Libby Spiers, Anurika P De Silva, David M Klyne, Melanie L Plinsinga, Ricardo J S Costa, Nicholas J Murphy, Wen Wu, Fiona L Dobson
{"title":"Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial.","authors":"Michelle Hall, Kim Allison, Gabrielle Knox, Fiona McManus, Rana S Hinman, Kim L Bennell, Libby Spiers, Anurika P De Silva, David M Klyne, Melanie L Plinsinga, Ricardo J S Costa, Nicholas J Murphy, Wen Wu, Fiona L Dobson","doi":"10.1016/S2665-9913(24)00373-4","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00373-4","url":null,"abstract":"<p><strong>Background: </strong>Exercise is recommended for hip osteoarthritis, but the most effective programmes for management of symptoms are unknown. We aimed to investigate whether adding aerobic physical activity to resistance exercise would improve hip pain and function more than resistance exercise alone in individuals with hip osteoarthritis.</p><p><strong>Methods: </strong>PHOENIX was a randomised comparative effectiveness trial done in Melbourne, Australia. We recruited people with a clinical diagnosis of symptomatic hip osteoarthritis. Participants were randomly assigned (1:1, by use of a web-based system) to aerobic physical activity and resistance exercise or resistance exercise only. Both groups received a home exercise programme and nine consultations with a physiotherapist over 3 months. The co-primary outcomes were change in hip pain severity (numerical rating scale [NRS] 0-10, with higher scores indicating worse outcomes) and function (Western Ontario and McMaster Osteoarthritis Index [WOMAC]; scale 0-68, with higher scores indicating worse outcomes) at 3 months. Analyses were done in the intention-to-treat population. People with lived experience of hip osteoarthritis were involved in the design of the study. This trial is registered with the Australian New Zealand Clinical Trial Registry (ACTRN 12619001297112), and is complete.</p><p><strong>Findings: </strong>Between Oct 15, 2019, and Sept 13, 2022, 196 participants (134 [68%] women and 62 [32%] men) were randomly assigned to aerobic physical activity and resistance exercise (n=97) or resistance exercise only (n=99). At 3 months, aerobic physical activity and resistance exercise was not more effective in improving hip pain severity (mean difference 0·3 [95% CI -0·3 to 0·8; p=0·36]) or function (mean difference -0·9 [95% CI -3·6 to 1·8; p=0·51]) compared with resistance exercise alone, with both showing a mean improvement in pain (2·4 [SD 1·9] with aerobic physical activity and resistance exercise vs 2·2 [2·1] with resistance exercise only) and function (7·0 [10·4] with aerobic physical activity and resistance exercise vs 8·9 [10·8] resistance exercise only). There were 24 related adverse events with aerobic physical activity and resistance exercise, and 31 with resistance exercise only, none of which were serious.</p><p><strong>Interpretation: </strong>Despite improvement in pain and function in both groups, adding moderate-intensity aerobic physical activity to resistance exercise did not lead to superior outcomes. Future work could consider higher intensity interval training before concluding no symptomatic benefit of adding aerobic exercise or physical activity to resistance exercise.</p><p><strong>Funding: </strong>National Health and Medical Research Council, Australia.</p>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing evidence gaps in exercise for hip osteoarthritis.
IF 15 1区 医学
Lancet Rheumatology Pub Date : 2025-02-05 DOI: 10.1016/S2665-9913(24)00378-3
Troels Kjeldsen, Inger Mechlenburg
{"title":"Addressing evidence gaps in exercise for hip osteoarthritis.","authors":"Troels Kjeldsen, Inger Mechlenburg","doi":"10.1016/S2665-9913(24)00378-3","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00378-3","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信